Skip Navigation

Home > Novel benzodiazepines: a review of the evidence of use and harms of novel benzodiazepines

Advisory Council on the Misuse of Drugs. (2020) Novel benzodiazepines: a review of the evidence of use and harms of novel benzodiazepines. London: Advisory Council on the Misuse of Drugs. 44 p.

[img]
Preview
PDF (Novel Benzodiazepines)
617kB

This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government.

This self-commissioned review follows an ACMD report published in 2016, which recommended 16 benzodiazepines for control under Class C of the UK Misuse of Drugs Act 1971 and Schedule 1 of the Misuse of Drugs Regulations 2001. Since then, several novel benzodiazepines have been identified in drugs seizures across Europe. Prompted by concerns of the abuse potential of these substances the ACMD have conducted a review to assess the available evidence on prevalence and harms of 13 novel benzodiazepines, to identify those that warrant further legislative control.


Item Type
Evidence resource
Publication Type
Guideline
Drug Type
CNS depressants
Intervention Type
AOD disorder, AOD disorder drug therapy, AOD disorder treatment method, AOD disorder harm reduction
Date
April 2020
Pages
44 p.
Publisher
Advisory Council on the Misuse of Drugs
Corporate Creators
Advisory Council on the Misuse of Drugs
Place of Publication
London
EndNote
Related URLs

Repository Staff Only: item control page